SavedAdd your journal

Journals / Fırat Üniversitesi Sağlık Bilimleri Tıp Dergisi / 2016 / Cilt: 30 - Sayı: 2

Evalutaion of Bone Mineral Disorder Markers in Elderly Hemodialysis Patients

Yaşlı Hemodiyaliz Hastalarında Mineral Kemik Bozukluğu Belirteçlerinin Değerlendirilmesi

Nevzat GÖZEL
Hülya TAŞKAPAN
Ramazan ULU
Hüseyin ÇELİKER
Ayhan DOĞUKAN
İrem Pembegül YİĞİT
Pages
77–81
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Serum intact parathyroid hormone (iPTH) levels were lower while vitamin D replacement and phosphorus binding medication were less in group II (P

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Chronic Kidney Disease (CKD) is a public health problem worldwide with increased prevalence.
📊
Key Findings & Data:Materials and Methods: 47 elderly HD patients undergoing maintenance HD were divided into two age groups: Group I early elderly (65-74 years old) and Group II mid elderly (75-84 years old).
💡
Conclusion & Impact:Serum intact parathyroid hormone (iPTH) levels were lower while vitamin D replacement and phosphorus binding medication were less in group II (P
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Chronic Kidney Disease (CKD) is a public health problem worldwide with increased prevalence. Chronic Kidney Disease-Mineral and Bone Disorders (CKD-MBD), which are commonly seen in CKD, have been considered to be the important cause of morbidity and mortality. We aimed to evaluate bone mineral markers and treatments that are performed in different age groups of elderly hemodialysis (HD) patients in routine follow up. Materials and Methods: 47 elderly HD patients undergoing maintenance HD were divided into two age groups: Group I early elderly (65-74 years old) and Group II mid elderly (75-84 years old). Features of the groups and differences in laboratory parameters and treatment administrations between groups were analyzed. Results: The mean age was 72.9±4.5 years. A total of 51.1% of patients were women and 40.4 % had diabetes mellitus (DM). Serum intact parathyroid hormone (iPTH) levels were lower while vitamin D replacement and phosphorus binding medication were less in group II (P

Özet

Amaç: Kronik böbrek hastalığı (KBH) tüm dünyada sıklığı artmakta olan bir halk sağlığı problemidir. KBH'da sık görülen Kronik Böbrek Hastalığı-Mineral ve Kemik Bozukluğunun (KBHMKB) önemli bir morbidite ve mortalite sebebi olduğu düşünülmektedir. Bu çalışmada, takip edilen yaşlı hemodiyaliz (HD) hastalarında farklı yaş gruplarına göre kemik metabolizma belirteçleri ve aldıkları tedavilerin değerlendirilmesi amaçlanmıştır. Gereç ve Yöntem: HD tedavisi olmakta olan yaşlı 47 hasta yaş gruplarına göre Grup I erken ileri yaşlı (65-74 yaş arası) ve Grup II orta ileri yaşlı (75-84 yaş arası) olarak ayrıldı. Grup özellikleri ve iki grup arasında laboratuvar parametreleri ve uygulanan tedaviler açısından farklılıklar incelendi. Bulgular: Ortalama yaş 72.9±4.5 yıl idi. Hastaların %51.1'i kadın idi ve %40.4'ünde diabetes mellitus (DM) vardı. Serum intakt parathormon (iPTH) düzeyleri, vitamin D ve fosfor bağlayıcı kullanım oranı Group II' de daha az idi (P

🔖

Cite This Article

GÖZEL, N., TAŞKAPAN, H., ULU, R., ÇELİKER, H., DOĞUKAN, A., YİĞİT, İ. P. (2022). Evalutaion of Bone Mineral Disorder Markers in Elderly Hemodialysis Patients. Fırat Üniversitesi Sağlık Bilimleri Tıp Dergisi, Cilt: 30 - Sayı: 2, 77–81. https://ajindex.com/articles/514581

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Martin KJ, Olgaard K, Coburn JW, et al. Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. Am J Kidney Dis 2004; 43: 558- 565. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD- MBD). Kidney Int Suppl 2009; 113: 1-130. Sprague SM. The role of the bone biopsy in the diagnosis of renal osteodystrophy. Semin Dial 2000; 13: 152-155.
  2. Moe S, Drüeke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945-1953.
  3. Tazza L, Di Napoli A, Bossola M, et al. Ageing of patients on chronic dialysis: Effects on mortality - a 12 - year study Nephrol Dial Transplant 2009; 24: 940-947.
  4. Jassal SV, Douglas JF, Stout RW. Prevalence of central autonomic neuropathy in elderly dialysis patients. Nephrol Dial Transplant 1998; 13: 1702-1708.
  5. Roberts RG, Kenny RA, Brierley EJ. Are elderly haemodialysis patients at risk of falls and postural hypotension? Int Urol Nephrol 2003; 35: 415-421.
  6. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calciumxphosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 1998; 31: 607-617.
  7. Drechsler C, Krane V, Grootendorst DC, et al. The association between parathyroid hormone and mortality in dialysis patients is modified by wasting. Nephrol Dial Transplant. 2009; 24: 3151-3157.
  8. Fang Y, Ginsberg C, Sugatani T, et al. Early chronic kidney disease-mineral calcification. Kidney Int 2014; 85: 142-150. disorder stimulates vascular National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42: 1-201.
  9. Floege J, Kim J, Ireland E, et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 2011; 26: 1948-1955.
  10. Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780.
  11. Palmer SC, Hayen A, Macaskill P, et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease. A syste